Investigational Drug Services in Clinical Trials with Kevin Zinchuk

Introduction

Investigational drug clinical trials depend on far more than protocol design, patient recruitment, and data collection. A critical part of trial execution is the pharmacy team responsible for supporting the study.

These specialized pharmacy teams are often known as Investigational Drug Services, or IDS. They help ensure that the right investigational drug, at the right dose, is administered to the right participant, at the right time, and in compliance with the clinical trial protocol.

In this episode of the Clinical Trial Podcast, Dr. Kevin Zinchuk joins the conversation to explain the role of Investigational Drug Services in modern clinical trials.

Kevin is the Pharmacy Manager for Investigational Drug Services at Brigham and Women’s Hospital, where he works closely with researchers across the public and private sectors to conceptualize, develop, and operationalize interventional clinical trials.

He also serves as the Program Director for Brigham and Women’s Hospital’s PGY2 Investigational Drugs and Research Pharmacy Residency. Kevin has published and presented on investigational drug and compounding practice and holds the Certified Clinical Research Professional credential through SOCRA.

In this conversation, Kevin shares how Investigational Drug Services support clinical trial execution, what sponsors and study teams should understand about pharmacy operations, and how stronger collaboration with IDS can improve the conduct of clinical trials.

What You’ll Learn

A simple framework for designing observational studies
When observational studies are more appropriate than RCTs
The biggest threats to validity: bias, confounding, and chance
How to interpret associations vs. causal effects
Practical strategies for handling confounders in analysis
How to build intuition for statistics – even if you struggle with it

About the Guest:

Connect with Kevin Zinchuk (https://www.linkedin.com/in/kevin-zinchuk-pharmd-mph-ccrp-21869931/)

Company: Brigham and Women’s Hospital

Selected Links from the Episode:

Organizations, Institutions, and Professional Programs

Regulations, Standards, and Regulatory Resources

Investigational Drug Service Practice Resources

Professional Publications and Career Resources

Related Episodes

Books:

Show Notes

[0:20] Kunal’s Introduction to Investigational Drug Services and Dr. Kevin Zinchuk

Investigational drug services help ensure that the correct study drug and dose reach the correct participant at the appropriate time.
Pharmacy teams must conduct this work in accordance with the protocol and applicable clinical research requirements.
Kevin is the Pharmacy Manager for Investigational Drug Services at Brigham and Women’s Hospital.
His work includes helping researchers conceptualize, develop, and operationalize interventional studies.
He collaborates with pharmacy leaders across Mass General Brigham, Dana-Farber Cancer Institute, and other academic medical centers.
Kevin directs the Brigham and Women’s Hospital PGY2 Investigational Drugs and Research Pharmacy Residency.
He holds a PharmD from MCPHS and a CCRP certification through SOCRA.
The episode will examine how IDS affects trial design, startup, enrollment, safety, compliance, and execution.

[2:49] Kevin Joins the Podcast

Kunal welcomes Kevin and recalls meeting him at a conference in Saudi Arabia.
Kevin thanks Kunal for the invitation and the opportunity to discuss investigational drug practice.

[2:52] Kevin’s Career Journey into Clinical Trials

Kevin says he “stumbled” into clinical research, as many professionals do.
He was interested in research and development, science, chemistry, mathematics, and biology from an early stage.
When he entered pharmacy school, he imagined working for a pharmaceutical company and developing new drugs.
An internship at Brigham and Women’s Hospital exposed him to the academic medical-center environment.
The research culture at Brigham and neighboring institutions increased his interest in investigational therapies.

[6:07] Pharmacy Education and the PharmD Pathway

Kunal asks whether Kevin completed a traditional undergraduate pharmacy degree.
Kevin explains that the historical bachelor’s degree in pharmacy was largely replaced by the Doctor of Pharmacy pathway.
His PharmD was a six-year program consisting of approximately two years of foundational education and four years of professional pharmacy education.
The degree prepared him for clinical pharmacy practice rather than functioning as a separate undergraduate and graduate sequence.

[7:01] Broad Pharmacy Internship Experience and the “Mysterious Door”

There were no formal IDS roles for pharmacy interns when Kevin trained at Brigham.
He worked in central inpatient distribution, sterile compounding, perioperative pharmacy, narcotics management, and anticoagulation services.
After rotating through nearly every area available to an intern, Kevin asked about the work occurring behind the “mysterious door” of the investigational drug pharmacy.
Although he could not enter IDS as an intern at the time, his interest became known to pharmacy leadership.
After becoming manager, Kevin expanded opportunities for pharmacy interns to experience IDS practice.
He believes learners benefit from seeing how pharmacy contributes to the complete clinical trial process.

[9:08] Moving into Investigational Drug Services

Brigham offered Kevin a full-time position after he completed his PharmD.
Approximately six months later, a full-time IDS position became available.
Kevin joined IDS in 2011 and has worked in investigational drug practice ever since.
After several promotions and approximately nine years of IDS experience, he was asked to become the department’s manager.
He assumed the leadership position in 2020 during the COVID-19 pandemic.
The department was exceptionally busy supporting COVID-19 vaccine research at the time.

[9:45] How Investigational Drug Services Affects Trial Startup and Enrollment

IDS oversees the medication-management components of clinical trials so that physician investigators do not have to personally manage every pharmacy activity.
Pharmacy responsibilities can include receiving, storing, preparing, dispensing, documenting, reconciling, and disposing of investigational products.
Medication-management feasibility can affect whether a site can activate and enroll participants.
Sponsors, CROs, investigators, and pharmacies need to understand one another’s timelines and operating requirements.

[10:24] IDS at the Intersection of Safety, Compliance, and Feasibility

Kevin describes IDS as operating at the intersection of patient safety, regulatory compliance, and overall trial feasibility.
When medication-management processes work well, trials can move faster, operate more safely, and produce more reliable data.
When IDS is under-resourced, misunderstood, or given an unworkable protocol, downstream trial activities suffer.
Early pharmacy engagement allows operational risks to be identified before they become deviations or enrollment barriers.
Kevin connects this work to the quality-by-design principles in ICH E6(R3).
IDS specialists can critically review draft protocols and identify medication-management requirements that may be difficult to execute at research sites.

[13:09] When Sponsors Should Involve IDS

Kunal asks whether pharmacy should be consulted before or after the protocol is finalized.
Kevin recommends involving IDS before final protocol approval whenever possible.
Once the protocol is signed, site-level feedback may arrive too late to produce meaningful change.
A site initiation visit should not be the first time the pharmacy is asked whether the medication plan is workable.
Sponsors should include people with direct institutional and frontline pharmacy experience during protocol development.

[13:37] Consequences of Receiving Pharmacy Feedback Too Late

IDS may identify a serious operational problem during site initiation, only to be told that other sites appear able to follow the procedure.
The pharmacy may then be unable to implement the protocol safely or consistently.
Sponsors may not revisit the design until the study begins missing enrollment milestones.
Correcting the problem can require a protocol amendment, additional regulatory review, new IRB submissions, retraining, and revised site procedures.
Early stakeholder input can prevent those investments and reduce the risk of trial failure.
Operational impracticality can jeopardize the development of an otherwise promising agent.

[15:53] Using a Trusted Investigator and Site Pharmacy for Protocol Review

Sponsors frequently design a study with at least one trusted investigator or high-performing site in mind.
Kevin recommends asking that investigator to connect the sponsor with the site’s IDS team.
Pharmacy can review a draft protocol for feasibility before the study design is locked.
Collaborative and government-supported studies sometimes use this approach successfully.
Early review helps prevent pharmacy from becoming a bottleneck after activation.
Input from more than one type of site can reveal differences in resources, operating hours, storage capacity, and state requirements.

[17:41] Recurring Medication-Management Feasibility Problems

Kunal asks which protocol problems Kevin encounters repeatedly.
Unrealistic blinding requirements are among the most common.
The proposed workflow may look reasonable on paper but be impossible to execute in the setting where participants are treated.
Sponsors need to evaluate when the intervention will be needed, who will be available, where the product will be stored, and how quickly it must be prepared.

[17:56] Emergency Studies, Blinding, and 24/7 Availability

Myocardial infarction, stroke, and other acute events can occur at any hour.
Most IDS pharmacies are not staffed as continuous 24-hour operations.
A protocol that requires a specially trained unblinded pharmacist to prepare a blinded dose in the middle of the night may be infeasible.
Time-sensitive treatment windows make this especially important in emergency research.
Sponsors should determine whether ready-to-use blinded supplies, premixed infusion bags, secure automated storage, or another validated off-hours process is possible.
The protocol must reflect the actual staffing and medication-delivery environment at participating sites.
Pharmacy should help evaluate the approach before the study is launched.

[20:42] Packaging and Labeling for Real Pharmacy Storage Conditions

Investigational products are sometimes packaged without considering how hundreds of kits will be arranged in a refrigerator or freezer.
Kevin describes a situation in which a kit identifier appeared only on the face of each box.
When boxes had to be stacked, pharmacy personnel could not see the identifiers without moving and examining them individually.
Searching through approximately 200 refrigerated kits could require leaving the refrigerator door open.
That activity could cause a temperature excursion and lead to quarantine, sponsor notification, and additional documentation.
Sponsors can reduce this risk by printing identifiers on the front, side, and top of the package.
Practical packaging design improves dispensing efficiency and reduces the possibility of selecting the wrong kit.

[23:30] Principal Startup Takeaways for Sponsors

Engage the site investigator and IDS team before the protocol is finalized.
Ask pharmacy to review drug preparation, blinding, storage, labeling, and off-hours access.
Design investigational-product packaging around the way products will actually be stored.
A relatively small amount of early consultation can prevent amendments, deviations, enrollment delays, and temperature excursions.

[24:23] Building the Local IDS Workflow Before Site Activation

IDS must establish documentation and accountability processes for each new study.
Pharmacy staff may need to create accountability logs, dispensing records, preparation worksheets, and disposition records.
The investigational product and related orders may need to be built into the site’s electronic health record.
Staff must understand the pharmacy manual and local medication-management workflow.
Early access to final materials gives the IDS team time to complete this work before screening and enrollment begin.
Waiting until the last moment to deliver a pharmacy manual or conduct training can delay activation.

[26:22] Maintaining Operational Readiness After Startup

Once the study begins, the pharmacy must have the equipment and ancillary supplies needed to prepare and dispense the product.
IDS needs appropriate access to interactive response technology and other sponsor systems.
Pharmacy training with the sponsor or CRO should be documented.
Product-distribution plans must account for the time required to receive, inspect, reconcile, store, and release a shipment.
The pharmacy needs sufficient product on hand to support participant dosing when a participant becomes eligible.

[28:23] Delivery to the Hospital Is Not Delivery to the Pharmacy

A courier’s tracking system may show that a shipment arrived at a hospital even though the product is still at the loading dock.
Large institutions have internal receiving and distribution processes that can take hours or longer.
A CRA monitoring the courier website may assume that IDS can immediately release the product for dosing.
Asking pharmacy personnel to abandon other work and retrieve a package from a loading dock is not a reliable operating model.
Distribution plans need to account for the full journey from the central depot to the IDS storage location.
These details should be considered during quality-by-design discussions.

[29:25] Why Sponsors Use Just-in-Time Shipping

Sponsors may use just-in-time distribution when a study has many sites but low enrollment at each site.
Centralizing the supply can reduce the amount of expensive investigational product sitting unused in the field.
Limited stability or expiration dating may also influence inventory decisions.
However, a shipment delay, severe weather event, or internal hospital receiving delay can cause the site to miss a treatment opportunity.
A trial is already a substantial investment, and reducing inventory too aggressively can make successful execution less likely.
Sponsors need to balance product conservation against the risk of losing enrolled participants.

[30:39] Investigational-Product and Ancillary-Supply Waste

Kunal asks whether unused products and supplies represent a meaningful problem in clinical trials.
Kevin confirms that substantial amounts of material can remain unused.
Waste can occur when sites are activated and supplied but never enroll or dose a participant.
Product allocation should be informed by realistic enrollment forecasts and the site’s ability to identify eligible patients.

[31:28] Studies That Never Dispense a Single Dose

A pharmacy resident analyzed several years of dispensing activity within Kevin’s IDS program.
During the period examined, the pharmacy had investigational product on the shelf for more than 400 open studies.
Only approximately 220 of those studies dispensed product.
Roughly 160 to 180 studies had been set up and supplied but never dispensed a single dose.
Site activation and training do not guarantee that the investigator can identify eligible participants.
Trials involving narrowly defined populations require adequate screening systems and properly resourced study teams.
A site may appear operationally qualified yet still lack the patient-identification capability needed to enroll.

[33:38] What Makes the Brigham and Women’s Research Environment Successful

Kunal asks what smaller pharmacies and research programs can learn from Brigham and Women’s Hospital.
Kevin emphasizes the institution’s investment in clinical research infrastructure.
Pharmacy works closely with investigators, research administration, compliance personnel, and the IRB.
The broader research community collaborates rather than operating as disconnected departments.
The institution provides specialized services so investigators do not need to personally develop every operational capability.
The Center for Clinical Investigation can provide coordinators, budget templates, visit templates, nursing personnel, nurse practitioners, physician assistants, and dedicated clinical space.
Investigators can obtain services according to the specific needs of their studies.
This integrated ecosystem makes the institution a supportive environment for clinical research.

[36:23] IDS Standard Operating Procedures, Tools, and Templates

The Brigham and Women’s IDS program was established in 1980.
The department has developed tools for site qualification visits and site initiation visits.
Resources include templated accountability logs, disposition logs, preparation worksheets, and operational checklists.
How-to documents explain processes such as building order sets and configuring investigational products in electronic systems.
Kevin estimates that the IDS standard operating procedure manual is approximately 120 pages long.
Standardization reduces variability and recurring pain points.
The system still allows flexibility because each protocol and sponsor has different requirements.

[38:04] Where Sponsors Underestimate the IDS Workload

Sponsors may not fully understand what a licensed pharmacy can legally or operationally perform.
Each state has its own pharmacy laws and professional-practice requirements.
Pharmacists must reconcile protocol instructions with federal, state, and institutional rules.
Their professional licenses may be placed at risk when medication-handling practices are unsafe or noncompliant.
IDS responsibilities include accountability, storage, temperature monitoring, excursion reporting, deviation management, preparation, relabeling, barcoding, dispensing, reconciliation, and disposition.
Investigational products may arrive with labeling that does not meet the institution’s electronic medication-management requirements.
At Kevin’s institution, each investigational product placed on the pharmacy shelf must be barcoded.
These site-level activities create real labor and should be considered in budgets and startup timelines.

[41:11] The Training Burden for IDS Personnel

Kevin recalls a publication from a Montreal IDS program that evaluated protocol-specific training workload.
He remembers the study estimating approximately 19 staff-hours for a complete round of training on one protocol.
The burden becomes substantial when a pharmacy supports 100 or more active protocols.
Staff turnover creates an additional challenge because every new employee must complete institutional, system, and protocol-specific training.
Requiring several hours of training for every active protocol could prevent a new employee from becoming independently operational for an extended period.
Repeated protocol amendments create further retraining and change-management work.
Amendments may require changes to electronic orders, accountability records, preparation instructions, and dispensing workflows.
Kevin’s site may support approximately 350 active trials, so no single study can be treated as the pharmacy’s only priority.

[43:40] Effective Training Methods for Research Pharmacies

IDS teams appreciate self-paced training that can be completed around patient-care and dispensing responsibilities.
Kevin’s department often designates one primary pharmacy contact to complete the sponsor’s comprehensive training.
That individual then disseminates the operationally relevant information to the remaining IDS staff.
Sponsors should distinguish between the full protocol and the information pharmacy personnel need for daily execution.
Pharmacy-specific training is more useful than requiring all personnel to complete unrelated study modules.
A one-on-one session between the CRA and the primary IDS representative can be effective.
Some sites prefer to review the pharmacy manual independently and document completion with a signed training record.
Sponsors that respect a validated local training model reduce unnecessary burden without sacrificing compliance.

[45:42] How Protocol Amendments Affect IDS

Sponsors and study teams should notify IDS before an amendment is implemented.
Pharmacy needs to determine whether the amendment changes electronic orders, dispensing instructions, documentation, storage, preparation, or accountability.
Major amendments generally require IRB approval before implementation.
The pharmacy may need to continue working under the previous protocol version until the new version becomes effective.
Participants may need to be reconsented before receiving treatment under the amended procedures.
Timing must be coordinated so that the correct protocol version is applied to each participant.
Frequent or serial amendments create a resource-intensive and high-risk change-management process.

[47:39] Common IND and Study-Documentation Mistakes

Incomplete, unclear, or nonexistent pharmacy manuals can prevent IDS from implementing a study.
Pharmacy should not receive investigational product and an instruction to begin enrollment before receiving the manual.
The manual must clearly describe preparation, storage, labeling, accountability, stability, and disposition.
Sponsors should avoid assuming that the pharmacy can resolve missing technical information immediately before first-patient dosing.
Pharmacy concerns discovered during startup may require sponsor, regulatory, manufacturing, or medical input.

[49:30] Stability, Beyond-Use Dating, Labeling, and Storage Assumptions

Protocols and pharmacy manuals sometimes include stability or beyond-use dating that the pharmacy cannot support.
Pharmacy cannot assign dating that conflicts with USP standards or lacks sufficient supporting information.
Product labeling needs to support accurate identification and safe medication use.
ISMP has described product-related investigational drug issues and strategies for preventing medication errors.
Sponsors should evaluate whether storage-temperature requirements and excursion-reporting expectations are operationally reasonable.
Extremely restrictive excursion rules can trigger repeated quarantines and sponsor inquiries without improving participant safety.
Packaging, labeling, storage, stability, and distribution should be evaluated as one integrated medication-use process.

[51:15] Communication and Personnel Turnover

Changes in CRAs, sponsor personnel, CRO staff, coordinators, and other study-team members can interrupt continuity.
New personnel may not understand decisions made during startup or previous monitoring visits.
Pharmacy staff and the principal investigator may be among the few people who remain involved for the entire study.
Inadequate handoffs can result in repeated questions and conflicting instructions.
Sponsors and CROs need clear communication pathways and documented transfer of responsibilities.
IDS should not have to repeatedly reconstruct the history of the study for each new monitor.

[54:35] Sponsor and CRO Document Repository Problems

Kevin describes monitors reviewing accountability records, temperature logs, and participant-specific dispensing records during recurring visits.
After a monitor leaves, the replacement may request the same historical records again.
This suggests that materials supplied to the previous monitor were not retained in an accessible sponsor or CRO repository.
Sites may be asked to reproduce years of documents that were already reviewed and provided.
Repeated production consumes pharmacy resources without adding value.
Sponsors and CROs should maintain organized, accessible site-level records throughout the trial.
Effective document management supports inspection readiness and continuity when personnel change.
Sites are expected to maintain robust systems, and it is reasonable to expect sponsors and CROs to do the same.

[58:23] Major Pharmacy Compliance Risks for Sponsors

Smaller and early-stage sponsors may have limited familiarity with pharmacy-practice requirements.
Protocol instructions must comply with standards for sterile compounding, controlled substances, and hazardous-drug handling.
A pharmacy may be unable to apply the dating, preparation process, or distribution method requested by the sponsor.
These conflicts should be identified before the protocol is finalized and enrollment begins.
Sponsors need access to people who understand both clinical research requirements and pharmacy law.
Compliance cannot be achieved by asking a pharmacy to perform work that its license or professional standards prohibit.

[1:01:28] Interstate Distribution in Investigator-Initiated Studies

Investigator-initiated studies may ask a hospital pharmacy to purchase, compound, and ship medication to sites across the country.
A hospital-licensed pharmacy may not be permitted to distribute investigational products across state lines in the proposed manner.
State-licensed compounding pharmacies should not be used as substitutes for properly qualified drug manufacturers.
The first option is to determine whether participating sites have local IDS pharmacies capable of preparing the product.
When local preparation is not possible, the investigator may need an FDA-registered manufacturer, central pharmacy, or qualified third-party logistics provider.
These solutions may substantially affect the study budget.
Multi-center studies supported by NIH R01-type funding can be difficult to launch because of manufacturing, distribution, state-law, and federal requirements.
IDS leaders continue to work toward clearer best practices for these research models.

[1:03:09] Pharmacy Best-Practice Guidelines and Standards

The United States Pharmacopeia is a foundational source of pharmacy-practice standards.
Large academic medical centers may also be subject to Joint Commission requirements.
ASHP published guidance for managing investigational drug products.
HOPA has developed best-practice standards for investigational drug services.
NCCN-affiliated pharmacy leaders have published recommendations for investigational drug practice.
The American Pharmacists Association has published a textbook focused on IDS pharmacy.
Sponsors and clinical operations professionals can use these materials to understand the requirements influencing site-pharmacy decisions.

[1:04:32] Professional Communities and Peer Learning

National and regional groups help IDS professionals address shared operational problems.
ASHP Connect includes a community for investigational drug practitioners.
The Society of Research Clinicians was developed by research-pharmacy leaders and helps professionals collaborate on common issues.
Peer networks allow practitioners to learn which approaches have succeeded or failed at other institutions.
Local and regional collaboratives can also reduce professional isolation.
Kevin emphasizes that IDS professionals are not alone in facing these challenges.
Open communication across institutions can help establish better standards for the field.

[1:07:10] Kevin’s Consulting Work with PROMETRIKA

Kevin joined PROMETRIKA through a former Brigham clinical research coordinator who later moved into the CRO sector.
His consulting work has included clinical operations and selected regulatory-compliance activities.
He has helped clients write pharmacy manuals and think through formulation-development questions.
His objective is to identify operational problems before they reduce a study’s likelihood of success.
Kevin has also consulted for other institutions and volunteered through the Harvard T.H. Chan School of Public Health.
His international trial work has involved formulation, randomization, blinding, packaging, and labeling.
For one project, Kevin traveled to Ulaanbaatar, Mongolia, for approximately two weeks.
He received multiple pallets of study medication and helped repackage, code, and label the product locally so the trial could proceed.
Consulting has exposed him to a broad range of research designs and logistical challenges.

[1:10:04] The SOCRA CCRP Certification

Kunal asks how the Certified Clinical Research Professional credential affected Kevin’s development.
The SOCRA certification assesses knowledge of human research participant protections.
Relevant areas include IRB practice, codified federal regulations, IND requirements, device regulations, safety reporting, GCP, essential documents, and investigational-product storage and handling.
Preparing for the certification requires discipline and a willingness to study across the clinical research field.
Although the credential is not designed exclusively for pharmacists, it demonstrates that pharmacists are key research personnel.
The certification can help pharmacy professionals communicate more effectively with investigators, sponsors, CROs, and regulatory personnel.
Many investigational drug specialists view earning the CCRP credential as a professional accomplishment or “badge of honor.”

[1:12:49] Books, Media, and Kevin’s MPH Studies

Kevin has been pursuing a Master of Public Health degree.
Much of his recent reading has therefore consisted of textbooks rather than novels.
A health-equity course introduced him to books about Paul Farmer and global health.
Kevin recommends Tracy Kidder’s Mountains Beyond Mountains.
He describes the book as an inspirational account of Paul Farmer’s global health-equity work.
Other MPH coursework has included material on medication reimbursement and health insurance.
The transcript does not identify those textbook titles.
Kevin’s recent podcast listening has also been related primarily to his MPH program.

[1:14:11] Strengthening Professional Foundations Through Textbooks

Kunal says he increasingly gravitates toward textbooks as his career develops.
Textbooks can reinforce foundational concepts instead of focusing only on short-term trends.
Kunal expresses interest in seeing Kevin’s complete MPH reading list.
He recommends publications from the Regulatory Affairs Professionals Society.
He also mentions healthcare-compliance publications as useful professional references.
Clinical professionals do not need to become regulatory specialists to benefit from learning regulatory principles.

[1:16:41] Career Advice for Emerging Clinical Research Leaders

Kevin encourages early-career professionals to remain open to unfamiliar opportunities.
Professionals should not automatically reject a project merely because they are not already experts in the subject.
New skills can be developed by studying deeply and learning during the process.
Kevin sometimes accepts a future presentation on an unfamiliar topic and uses the preparation period to become knowledgeable.
Growth requires curiosity, effort, and a willingness to move beyond familiar responsibilities.
Professionals should make productive use of available time and continue expanding their knowledge.
Being hungry to learn can create opportunities that would not otherwise appear.
Kevin’s progression from intern to IDS manager reflects the value of seeking new experiences and volunteering for challenging work.

[1:18:16] Closing Thanks

Kunal thanks Kevin for sharing his time and investigational pharmacy expertise.
Kevin thanks Kunal for inviting him to the podcast.

[1:18:23] Clinical Trial Podcast Outro

Listeners are invited to visit the Clinical Trial Podcast website for additional clinical research content.

Major Themes

Early IDS engagement is a quality-by-design and feasibility strategy.
Investigational drug services should be involved before a protocol is finalized. Frontline pharmacy review can uncover unworkable blinding requirements, off-hours preparation problems, packaging deficiencies, unsupported stability assumptions, and distribution risks before they cause amendments, deviations, missed treatment windows, or enrollment failure.
Pharmacy operations represent a substantial but often underestimated workload.
IDS teams manage far more than product storage and dispensing. Their responsibilities include electronic system configuration, accountability, labeling, barcoding, temperature management, staff training, amendment implementation, documentation, reconciliation, and inspection support. Sponsors and CROs need realistic timelines, fit-for-purpose training, dependable document repositories, and continuity when personnel change.
Investigational-product management must comply with pharmacy law as well as the protocol.
A protocol cannot require a licensed pharmacy to violate USP standards, state law, institutional requirements, or professional-practice expectations. Multi-center and investigator-initiated studies may require local IDS support, qualified manufacturers, central pharmacies, or third-party logistics providers. Successful programs combine clinical, operational, regulatory, manufacturing, and pharmacy expertise.

Selected Quotes

“If the medication management aspects for a trial don’t work cleanly, the trial won’t succeed.”

“You’re not on an island.”

“Don’t be satisfied with what you have. Be hungry for more.”

Audience Question

At what point does your organization involve investigational drug services, and which medication-management risk could be eliminated by including pharmacy before the protocol is finalized?

Follow Us

Investigational Drug Services in Clinical Trials with Kevin Zinchuk

Introduction

What You’ll Learn

About the Guest:

Selected Links from the Episode:

Regulations, Standards, and Regulatory Resources

Investigational Drug Service Practice Resources

Professional Publications and Career Resources

Related Episodes

Show Notes

Major Themes

Selected Quotes

Audience Question

Leave a Reply Cancel reply

Follow Us

Investigational Drug Services in Clinical Trials with Kevin Zinchuk

Introduction

What You’ll Learn

About the Guest:

Selected Links from the Episode:

Regulations, Standards, and Regulatory Resources

Investigational Drug Service Practice Resources

Professional Publications and Career Resources

Related Episodes

Show Notes

Major Themes

Selected Quotes

Audience Question

How Statisticians Really Think About Endpoints, Power, and FDA Review with Roseann White

Leave a Reply Cancel reply